TrialPath
Recruiting

BEAT-SHOCK Registry

NCT07643610 · University Hospital, Basel, Switzerland
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry
About this study
This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.
Eligibility criteria
* Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay * Age ≥18 years * Provision of written ICF * Clinical diagnosis of cardiogenic shock. * impaired organ perfusion due to primary cardiac dysfunction, * persistent systolic blood pressure (SBP) \<90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and * evidence of systemic hypoperfusion with arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l and ≥1 of the following: * Cold or clammy extremities * Altered mental status * Reduced urine output * Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring) * Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l) and cardiac dysfunction are present and alternative causes are excluded Exclusion criteria: * Age \<18 years * Refusal to provide informed consent by the patient or their legally authorized representative
Study design
Enrollment target: 8000 participants
Age groups: adult, older_adult
Timeline
Starts: 2025-10-01
Estimated completion: 2035-10-01
Last updated: 2026-06-11
Interventions
Other: no internvention
Primary outcomes
  • • In-Hospital all-cause mortality occurring before discharge from the participating study centre (10 years)
Sponsor
University Hospital, Basel, Switzerland · other
Contacts & investigators
ContactJasper Boeddinghaus, PD Dr. med. · contact · jasper.boeddinghaus@usb.ch · 0041613287897
ContactGregor Leibundgut, Prof. Dr. · contact · gregor.leibundgut@usb.ch · 0041613287897
All locations (1)
University Hospital BaselRecruiting
Basel, Canton of Basel-City, Switzerland